The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients

Respiration

Volumn 82, Issue 4, 2011, Pages 341-350

  Wojas Krawczyk, Kamila ^a   Krawczyk, Paweł ^a   Mlak, Radosław ^a   Kucharczyk, Tomasz ^a   Kowalski, Dariusz M ^b   Krzakowski, Maciej ^b   Milanowski, Janusz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

EGFR gene mutation; Erlotinib; Non small cell lung cancer; Predictive index

Indexed keywords

ERLOTINIB; LACTATE DEHYDROGENASE; VASCULOTROPIN;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENDER; GENE MUTATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RASH; RISK FACTOR; SCORING SYSTEM; SMOKING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KARNOFSKY PERFORMANCE STATUS; LIPOPROTEINS, HDL; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; WEIGHT LOSS;

EID: 80052967415     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000322843     Document Type: Article

References (22)

1. Hirsch FR, Varella-Garcia M, McCoy J, West H, Xavier AC, Gumerlock P, et al: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-6845.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al: Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med 2005;14:123-132. (Pubitemid 41058344)
3. Florescu M, Hasan B, Seymour L, Ding K, Shepherd FA, National Cancer Institute of Canada Clinical Trials Group: A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J Thorac Oncol 2008;3:590-598. (Pubitemid 351787301)
4. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
5. Mitsudomi T, Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007;98:1817-1824. (Pubitemid 350002184)
6. Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Eng J Med 2009;361:947-957.
7. Paz-Ares L, Soulieres D, Melezinek I, Moecks J, Keil L, Mok T, et al: Clinical outcome in non-small cell lung cancer patients with EGFR mutation: pooled analysis. J Cell Mol Med 2010;14:51-69.
8. Zhang X, Chang A: Molecular predictors of EGFR-TKI sensitivity In advanced nonsmall cell lung cancer. Int J Med Sci 2008;5:209-217.
9. Zhu HQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al: Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268-4275.
10. Hirsch FR, Bunn PA: EGFR testing in lung cancer is ready for prime time. Lancet Oncol 2009;10:432-433.
11. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655. (Pubitemid 40812628)
12. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, et al: Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007;18:752-760. (Pubitemid 46523281)
13. Pan Q, Pao W, Ladanyi M: Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396-403. (Pubitemid 41149655)
14. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;1:1589-1597. (Pubitemid 41079796)
15. Weiss GJ, Rosell R, Fossella F, Perry M, Stahel R, Barata F, et al: The impact of induction chemotherapy on the outcome of secondline therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2007;18:453-460. (Pubitemid 46359622)
16. Clark GM: Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol 2008;1:406-412.
17. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al: Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2006;355:133-144.
18. Breuer RHJ, Postmus PE, Smit EF: Molecular pathology of non-small cell lung cancer. Respiration 2005;72:313-330. (Pubitemid 40981094)
19. Pan J, Han J, Wu J, Huang H, Yu Q, Sheng L: MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to deocetaxel-cisplatin chemotherapy in patients with non-small cell lung cancer. Respiration 2009;78:49-55.
20. Schneider CP, Heigener D, Schott-von-Romer K, Gütz S, Laack E, Digel W, et al: Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer. J Thorac Oncol 2008;3:1446-1453.
21. Soulieres D. Ciuleanu T, Stelmakh L: Is there a relationship between increased EGFR gene copy number and the presence of activating EGFR mutations in advanced NSCLC? 13th World Conference on Lung Cancer, 2009. Abstract A3.6.
22. Toyooka S, Matsuo K, Shigemat su H, Kosaka T, Tokumo M, Yatabe Y, et al; The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non-small cell lung cancer. Clin Cancer Res 2007;13:5763-5768. (Pubitemid 47583901)